Vatalanib hydrochloride

Cat. No.:	HY-12018A
CAS No.:	212141-52-1
Molecular Formula:	$C_{20}H_{16}Cl_2N_4$
Molecular Weight:	383.27
Target:	VEGFR; Apoptosis
Pathway:	Protein Tyrosine Kinase/RTK; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Vatalanib (PTK787; ZK-222584; CGP-797870) hydrochloride is an inhibitor of VEGFR2/KDR with an IC_{50} of 37 nM[1].

CUSTOMER VALIDATION

- Bioact Mater. 2 January 2022.
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
- J Pharm Anal. 2023 Sep 11.
- Br J Pharmacol. 2019 Sep;176(17):3143-3160.
- Oncol Rep. 2016 Mar;35(3):1297-308.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Wood JM, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000;60(8):2178-2189.

[2]. Murakami M, et al. Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. Ann Surg Oncol. 2011;18(2):589-596.

[3]. Wan J, et al. Local recurrence of small cell lung cancer following radiofrequency ablation is induced by HIF-1α expression in the transition zone. Oncol Rep. 2016;35(3):1297-1308.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA